Balto Pharmaceuticals
San Diego, United States· Est. 2018
To improve patient outcomes by developing first-in-class small molecule inhibitors of protein-protein interactions for the safe and effective treatments for cancer.
Private Company
Funding information not available
About
To improve patient outcomes by developing first-in-class small molecule inhibitors of protein-protein interactions for the safe and effective treatments for cancer.
OncologySmall Molecules